Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-09

AUTHORS

Daniel A Pollyea, Martin S Tallman, Stéphane de Botton, Hagop M Kantarjian, Robert Collins, Anthony S Stein, Mark G Frattini, Qiang Xu, Alessandra Tosolini, Wendy L See, Kyle J MacBeth, Samuel V Agresta, Eyal C Attar, Courtney D DiNardo, Eytan M Stein

ABSTRACT

Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy historically have poor outcomes. Approximately 12-15% of older patients with AML harbor isocitrate dehydrogenase 2 (IDH2) gene mutations. Enasidenib is an oral inhibitor of mutant IDH2 proteins. Among 39 patients with newly diagnosed mutant-IDH2 AML who received enasidenib monotherapy in this phase I/II trial, median age was 77 years (range 58-87) and 23 patients (59%) had had an antecedent hematologic disorder. The median number of enasidenib treatment cycles was 6.0 (range 1-35). The most common treatment-related adverse events were indirect hyperbilirubinemia (31%), nausea (23%), and fatigue, decreased appetite, and rash (18% each). Treatment-related grade 3-4 cytopenias were reported for eight patients (21%); there was no treatment-related grade 3-4 infections. Twelve patients achieved a response (overall response rate 30.8% [95% CI 17.0%, 47.6%]), including seven patients (18%) who attained complete remission. At a median follow-up of 8.4 months, the median duration of any response was not reached (NR). Median overall survival for all patients was 11.3 months (95% CI 5.7, 15.1), and was NR for responders. Oral, outpatient targeted treatment with enasidenib may benefit older adults with newly diagnosed mutant-IDH2 AML who are not candidates for cytotoxic regimens. More... »

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41375-019-0472-2

DOI

http://dx.doi.org/10.1038/s41375-019-0472-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113327841

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30967620


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Colorado Anschutz Medical Campus", 
          "id": "https://www.grid.ac/institutes/grid.430503.1", 
          "name": [
            "Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA. daniel.pollyea@ucdenver.edu."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pollyea", 
        "givenName": "Daniel A", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tallman", 
        "givenName": "Martin S", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Universit\u00e9 Paris-Sud, Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre, France.", 
            "Gustave Roussy, D\u00e9partement d'h\u00e9matologie et D\u00e9partement d'innovation Th\u00e9rapeutique, F-94805, Villejuif, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Botton", 
        "givenName": "St\u00e9phane", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "The University of Texas MD Anderson Cancer Center, Houston, TX, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kantarjian", 
        "givenName": "Hagop M", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas Southwestern Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.267313.2", 
          "name": [
            "UT Southwestern Medical Center, Dallas, TX, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Collins", 
        "givenName": "Robert", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "City Of Hope National Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "City of Hope Comprehensive Cancer Center, Duarte, CA, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stein", 
        "givenName": "Anthony S", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Celgene (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418722.a", 
          "name": [
            "Celgene Corporation, Summit, NJ, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Frattini", 
        "givenName": "Mark G", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Celgene (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418722.a", 
          "name": [
            "Celgene Corporation, Summit, NJ, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xu", 
        "givenName": "Qiang", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Celgene (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418722.a", 
          "name": [
            "Celgene Corporation, Summit, NJ, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tosolini", 
        "givenName": "Alessandra", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Celgene (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418722.a", 
          "name": [
            "Celgene Corporation, Summit, NJ, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "See", 
        "givenName": "Wendy L", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Celgene (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418722.a", 
          "name": [
            "Celgene Corporation, Summit, NJ, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "MacBeth", 
        "givenName": "Kyle J", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Agios Pharmaceuticals (United States)", 
          "id": "https://www.grid.ac/institutes/grid.427815.d", 
          "name": [
            "Agios Pharmaceuticals, Inc., Cambridge, MA, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Agresta", 
        "givenName": "Samuel V", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Agios Pharmaceuticals (United States)", 
          "id": "https://www.grid.ac/institutes/grid.427815.d", 
          "name": [
            "Agios Pharmaceuticals, Inc., Cambridge, MA, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Attar", 
        "givenName": "Eyal C", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "The University of Texas MD Anderson Cancer Center, Houston, TX, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "DiNardo", 
        "givenName": "Courtney D", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cornell University", 
          "id": "https://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.", 
            "Weill Cornell Medical College, New York, NY, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stein", 
        "givenName": "Eytan M", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1182/blood-2015-01-621664", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001692236"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.3460", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007602046"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2011.342", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008195860", 
          "https://doi.org/10.1038/leu.2011.342"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2010.11.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010196923"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2010.11.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010196923"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmra1406184", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011899386"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2012.065151", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013692359"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08617", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016136939", 
          "https://doi.org/10.1038/nature08617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08617", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016136939", 
          "https://doi.org/10.1038/nature08617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1516192", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016166624"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2014-11-610543", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017221703"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.35.4894", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017658510"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21723", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017840415"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21723", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017840415"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1301689", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025463655"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1038/embor.2011.43", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028756238"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2012.066100", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032557350"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2014.216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039463360", 
          "https://doi.org/10.1038/leu.2014.216"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1005143", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040018409"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-015-2351-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041404713", 
          "https://doi.org/10.1007/s00277-015-2351-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-015-2351-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041404713", 
          "https://doi.org/10.1007/s00277-015-2351-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2013.269", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042586678", 
          "https://doi.org/10.1038/leu.2013.269"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2013.269", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042586678", 
          "https://doi.org/10.1038/leu.2013.269"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/10428190701809172", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042924274"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2012-02-412296", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044042486"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2010.12.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044538954"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.38.9429", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052466310"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.04.036", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203515"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078854996", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083319627", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/2159-8290.cd-16-1034", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083811679"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2017-04-779405", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085900698"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2017-04-779447", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085900699"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2017.4695", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100471440"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/bloodadvances.2017015222", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105462396"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/bloodadvances.2017015222", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105462396"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/bloodadvances.2017015222", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105462396"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.77.6112", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105710853"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41375-018-0257-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107328181", 
          "https://doi.org/10.1038/s41375-018-0257-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41375-018-0257-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107328181", 
          "https://doi.org/10.1038/s41375-018-0257-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2018-08-869008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110380829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2018-08-869008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110380829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2018-08-869008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110380829"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-09", 
    "datePublishedReg": "2019-04-09", 
    "description": "Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy historically have poor outcomes. Approximately 12-15% of older patients with AML harbor isocitrate dehydrogenase 2 (IDH2) gene mutations. Enasidenib is an oral inhibitor of mutant IDH2 proteins. Among 39 patients with newly diagnosed mutant-IDH2 AML who received enasidenib monotherapy in this phase I/II trial, median age was 77 years (range 58-87) and 23 patients (59%) had had an antecedent hematologic disorder. The median number of enasidenib treatment cycles was 6.0 (range 1-35). The most common treatment-related adverse events were indirect hyperbilirubinemia (31%), nausea (23%), and fatigue, decreased appetite, and rash (18% each). Treatment-related grade 3-4 cytopenias were reported for eight patients (21%); there was no treatment-related grade 3-4 infections. Twelve patients achieved a response (overall response rate 30.8% [95% CI 17.0%, 47.6%]), including seven patients (18%) who attained complete remission. At a median follow-up of 8.4 months, the median duration of any response was not reached (NR). Median overall survival for all patients was 11.3 months (95% CI 5.7, 15.1), and was NR for responders. Oral, outpatient targeted treatment with enasidenib may benefit older adults with newly diagnosed mutant-IDH2 AML who are not candidates for cytotoxic regimens.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/s41375-019-0472-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1097065", 
        "issn": [
          "0887-6924", 
          "1476-5551"
        ], 
        "name": "Leukemia", 
        "type": "Periodical"
      }
    ], 
    "name": "Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41375-019-0472-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113327841"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8704895"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30967620"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41375-019-0472-2", 
      "https://app.dimensions.ai/details/publication/pub.1113327841"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000375_0000000375/records_91438_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://www.nature.com/articles/s41375-019-0472-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41375-019-0472-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41375-019-0472-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41375-019-0472-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41375-019-0472-2'


 

This table displays all metadata directly associated to this object as RDF triples.

270 TRIPLES      20 PREDICATES      57 URIs      16 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41375-019-0472-2 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N2409576ed15146b5924a51aa13928c95
4 schema:citation sg:pub.10.1007/s00277-015-2351-x
5 sg:pub.10.1038/leu.2011.342
6 sg:pub.10.1038/leu.2013.269
7 sg:pub.10.1038/leu.2014.216
8 sg:pub.10.1038/nature08617
9 sg:pub.10.1038/s41375-018-0257-z
10 https://app.dimensions.ai/details/publication/pub.1078854996
11 https://app.dimensions.ai/details/publication/pub.1083319627
12 https://doi.org/10.1001/jamaoncol.2017.4695
13 https://doi.org/10.1002/cncr.21723
14 https://doi.org/10.1016/j.ccr.2010.11.015
15 https://doi.org/10.1016/j.ccr.2010.12.014
16 https://doi.org/10.1038/embor.2011.43
17 https://doi.org/10.1056/nejmoa1005143
18 https://doi.org/10.1056/nejmoa1301689
19 https://doi.org/10.1056/nejmoa1516192
20 https://doi.org/10.1056/nejmra1406184
21 https://doi.org/10.1080/10428190701809172
22 https://doi.org/10.1158/2159-8290.cd-16-1034
23 https://doi.org/10.1182/blood-2012-02-412296
24 https://doi.org/10.1182/blood-2014-11-610543
25 https://doi.org/10.1182/blood-2015-01-621664
26 https://doi.org/10.1182/blood-2017-04-779405
27 https://doi.org/10.1182/blood-2017-04-779447
28 https://doi.org/10.1182/blood-2018-08-869008
29 https://doi.org/10.1182/bloodadvances.2017015222
30 https://doi.org/10.1200/jco.2003.04.036
31 https://doi.org/10.1200/jco.2011.35.4894
32 https://doi.org/10.1200/jco.2011.38.9429
33 https://doi.org/10.1200/jco.2017.77.6112
34 https://doi.org/10.18632/oncotarget.3460
35 https://doi.org/10.3324/haematol.2012.065151
36 https://doi.org/10.3324/haematol.2012.066100
37 schema:datePublished 2019-04-09
38 schema:datePublishedReg 2019-04-09
39 schema:description Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy historically have poor outcomes. Approximately 12-15% of older patients with AML harbor isocitrate dehydrogenase 2 (IDH2) gene mutations. Enasidenib is an oral inhibitor of mutant IDH2 proteins. Among 39 patients with newly diagnosed mutant-IDH2 AML who received enasidenib monotherapy in this phase I/II trial, median age was 77 years (range 58-87) and 23 patients (59%) had had an antecedent hematologic disorder. The median number of enasidenib treatment cycles was 6.0 (range 1-35). The most common treatment-related adverse events were indirect hyperbilirubinemia (31%), nausea (23%), and fatigue, decreased appetite, and rash (18% each). Treatment-related grade 3-4 cytopenias were reported for eight patients (21%); there was no treatment-related grade 3-4 infections. Twelve patients achieved a response (overall response rate 30.8% [95% CI 17.0%, 47.6%]), including seven patients (18%) who attained complete remission. At a median follow-up of 8.4 months, the median duration of any response was not reached (NR). Median overall survival for all patients was 11.3 months (95% CI 5.7, 15.1), and was NR for responders. Oral, outpatient targeted treatment with enasidenib may benefit older adults with newly diagnosed mutant-IDH2 AML who are not candidates for cytotoxic regimens.
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree false
43 schema:isPartOf sg:journal.1097065
44 schema:name Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
45 schema:productId N2130456725cd4d9e8d7420f015511b57
46 N7e1ee6807d5a47a68d617b46016c1577
47 N88f7ec2f608340ae8a0676709ee326f8
48 Nf26ebb8b66e04698a14c841f37d1744f
49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113327841
50 https://doi.org/10.1038/s41375-019-0472-2
51 schema:sdDatePublished 2019-04-15T09:00
52 schema:sdLicense https://scigraph.springernature.com/explorer/license/
53 schema:sdPublisher N1bb2cf3a2f564a489d1f813aca829fc6
54 schema:url http://www.nature.com/articles/s41375-019-0472-2
55 sgo:license sg:explorer/license/
56 sgo:sdDataset articles
57 rdf:type schema:ScholarlyArticle
58 N02f60d8e394e4dfc8b82a42aa1e73f09 schema:affiliation https://www.grid.ac/institutes/grid.427815.d
59 schema:familyName Agresta
60 schema:givenName Samuel V
61 rdf:type schema:Person
62 N033b6a90efe14076bb2e8321600e87a1 rdf:first Nd5d7955db9ba4b31a0363bb6ac05d7f6
63 rdf:rest N4e977b54a8934ae1b28675df3b4b7146
64 N09bd25fa667248818540b71fa1efe22c rdf:first N125c604c917d42b8baeac80225b36a53
65 rdf:rest N3740ae81254343a896126ee75678be80
66 N125c604c917d42b8baeac80225b36a53 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
67 schema:familyName Kantarjian
68 schema:givenName Hagop M
69 rdf:type schema:Person
70 N1bb2cf3a2f564a489d1f813aca829fc6 schema:name Springer Nature - SN SciGraph project
71 rdf:type schema:Organization
72 N1de4e2cce233474eb51761e901af52f8 schema:affiliation https://www.grid.ac/institutes/grid.418722.a
73 schema:familyName Xu
74 schema:givenName Qiang
75 rdf:type schema:Person
76 N20b1b29f4ac94411afd15b39eff3e971 rdf:first N4a17825a0dfa4da0943c99ef099fa513
77 rdf:rest Ne058adda63644e2b90fcf4e300a9085b
78 N2130456725cd4d9e8d7420f015511b57 schema:name pubmed_id
79 schema:value 30967620
80 rdf:type schema:PropertyValue
81 N2409576ed15146b5924a51aa13928c95 rdf:first Nda6218cdb7ca4711943469f58af2c0f9
82 rdf:rest N827e6d3fd8a24a34a84743640fef7405
83 N3740ae81254343a896126ee75678be80 rdf:first Ne42e882f3b0f49e3bd56f51f7228b0df
84 rdf:rest N99ad0e025c5149a99c6d3d2383f44c7f
85 N4286a56b6c0245c8a5a6cd4c965c8b2e schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
86 schema:familyName de Botton
87 schema:givenName Stéphane
88 rdf:type schema:Person
89 N442998bff084470095e103e88f94479d rdf:first Na9638e5d9f1f4b2580bf7377ff0acb60
90 rdf:rest N033b6a90efe14076bb2e8321600e87a1
91 N44adab4bd2cd480b8953b44c39f8a7b2 rdf:first Na0b103da29ee4a1597d4a0ab6a3493f0
92 rdf:rest Nf7fc72727d294c4eb879ae6be1a3a75a
93 N4a17825a0dfa4da0943c99ef099fa513 schema:affiliation https://www.grid.ac/institutes/grid.418722.a
94 schema:familyName Frattini
95 schema:givenName Mark G
96 rdf:type schema:Person
97 N4e977b54a8934ae1b28675df3b4b7146 rdf:first N02f60d8e394e4dfc8b82a42aa1e73f09
98 rdf:rest Nd6791b3d737e4409bf8b9c6ad59f7259
99 N6c809a63c160444a8762b17e0034b776 rdf:first Nca2cb59a81db4f3b839b24217ca9d5d9
100 rdf:rest N442998bff084470095e103e88f94479d
101 N71516d85a89d458fbba76ad7f7bf3bee schema:affiliation https://www.grid.ac/institutes/grid.410425.6
102 schema:familyName Stein
103 schema:givenName Anthony S
104 rdf:type schema:Person
105 N73ac1e15d9f14fb59a0688f8c7688c1d schema:affiliation https://www.grid.ac/institutes/grid.51462.34
106 schema:familyName Tallman
107 schema:givenName Martin S
108 rdf:type schema:Person
109 N7e1ee6807d5a47a68d617b46016c1577 schema:name nlm_unique_id
110 schema:value 8704895
111 rdf:type schema:PropertyValue
112 N827e6d3fd8a24a34a84743640fef7405 rdf:first N73ac1e15d9f14fb59a0688f8c7688c1d
113 rdf:rest Na8737d130dc046debc4b74e3afb66dc7
114 N88f7ec2f608340ae8a0676709ee326f8 schema:name dimensions_id
115 schema:value pub.1113327841
116 rdf:type schema:PropertyValue
117 N99ad0e025c5149a99c6d3d2383f44c7f rdf:first N71516d85a89d458fbba76ad7f7bf3bee
118 rdf:rest N20b1b29f4ac94411afd15b39eff3e971
119 Na02ccec77aac44eb90cba96d75431a14 schema:affiliation https://www.grid.ac/institutes/grid.5386.8
120 schema:familyName Stein
121 schema:givenName Eytan M
122 rdf:type schema:Person
123 Na0b103da29ee4a1597d4a0ab6a3493f0 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
124 schema:familyName DiNardo
125 schema:givenName Courtney D
126 rdf:type schema:Person
127 Na8737d130dc046debc4b74e3afb66dc7 rdf:first N4286a56b6c0245c8a5a6cd4c965c8b2e
128 rdf:rest N09bd25fa667248818540b71fa1efe22c
129 Na9638e5d9f1f4b2580bf7377ff0acb60 schema:affiliation https://www.grid.ac/institutes/grid.418722.a
130 schema:familyName See
131 schema:givenName Wendy L
132 rdf:type schema:Person
133 Nca2cb59a81db4f3b839b24217ca9d5d9 schema:affiliation https://www.grid.ac/institutes/grid.418722.a
134 schema:familyName Tosolini
135 schema:givenName Alessandra
136 rdf:type schema:Person
137 Nd5d7955db9ba4b31a0363bb6ac05d7f6 schema:affiliation https://www.grid.ac/institutes/grid.418722.a
138 schema:familyName MacBeth
139 schema:givenName Kyle J
140 rdf:type schema:Person
141 Nd6791b3d737e4409bf8b9c6ad59f7259 rdf:first Nda9ffc92820848ce9aedf065435ea421
142 rdf:rest N44adab4bd2cd480b8953b44c39f8a7b2
143 Nda6218cdb7ca4711943469f58af2c0f9 schema:affiliation https://www.grid.ac/institutes/grid.430503.1
144 schema:familyName Pollyea
145 schema:givenName Daniel A
146 rdf:type schema:Person
147 Nda9ffc92820848ce9aedf065435ea421 schema:affiliation https://www.grid.ac/institutes/grid.427815.d
148 schema:familyName Attar
149 schema:givenName Eyal C
150 rdf:type schema:Person
151 Ne058adda63644e2b90fcf4e300a9085b rdf:first N1de4e2cce233474eb51761e901af52f8
152 rdf:rest N6c809a63c160444a8762b17e0034b776
153 Ne42e882f3b0f49e3bd56f51f7228b0df schema:affiliation https://www.grid.ac/institutes/grid.267313.2
154 schema:familyName Collins
155 schema:givenName Robert
156 rdf:type schema:Person
157 Nf26ebb8b66e04698a14c841f37d1744f schema:name doi
158 schema:value 10.1038/s41375-019-0472-2
159 rdf:type schema:PropertyValue
160 Nf7fc72727d294c4eb879ae6be1a3a75a rdf:first Na02ccec77aac44eb90cba96d75431a14
161 rdf:rest rdf:nil
162 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
163 schema:name Medical and Health Sciences
164 rdf:type schema:DefinedTerm
165 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
166 schema:name Oncology and Carcinogenesis
167 rdf:type schema:DefinedTerm
168 sg:journal.1097065 schema:issn 0887-6924
169 1476-5551
170 schema:name Leukemia
171 rdf:type schema:Periodical
172 sg:pub.10.1007/s00277-015-2351-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1041404713
173 https://doi.org/10.1007/s00277-015-2351-x
174 rdf:type schema:CreativeWork
175 sg:pub.10.1038/leu.2011.342 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008195860
176 https://doi.org/10.1038/leu.2011.342
177 rdf:type schema:CreativeWork
178 sg:pub.10.1038/leu.2013.269 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042586678
179 https://doi.org/10.1038/leu.2013.269
180 rdf:type schema:CreativeWork
181 sg:pub.10.1038/leu.2014.216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039463360
182 https://doi.org/10.1038/leu.2014.216
183 rdf:type schema:CreativeWork
184 sg:pub.10.1038/nature08617 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016136939
185 https://doi.org/10.1038/nature08617
186 rdf:type schema:CreativeWork
187 sg:pub.10.1038/s41375-018-0257-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1107328181
188 https://doi.org/10.1038/s41375-018-0257-z
189 rdf:type schema:CreativeWork
190 https://app.dimensions.ai/details/publication/pub.1078854996 schema:CreativeWork
191 https://app.dimensions.ai/details/publication/pub.1083319627 schema:CreativeWork
192 https://doi.org/10.1001/jamaoncol.2017.4695 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100471440
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1002/cncr.21723 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017840415
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1016/j.ccr.2010.11.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010196923
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1016/j.ccr.2010.12.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044538954
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1038/embor.2011.43 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028756238
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1056/nejmoa1005143 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040018409
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1056/nejmoa1301689 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025463655
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1056/nejmoa1516192 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016166624
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1056/nejmra1406184 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011899386
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1080/10428190701809172 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042924274
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1158/2159-8290.cd-16-1034 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083811679
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1182/blood-2012-02-412296 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044042486
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1182/blood-2014-11-610543 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017221703
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1182/blood-2015-01-621664 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001692236
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1182/blood-2017-04-779405 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085900698
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1182/blood-2017-04-779447 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085900699
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1182/blood-2018-08-869008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1110380829
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1182/bloodadvances.2017015222 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105462396
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1200/jco.2003.04.036 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203515
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1200/jco.2011.35.4894 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017658510
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1200/jco.2011.38.9429 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052466310
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1200/jco.2017.77.6112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105710853
235 rdf:type schema:CreativeWork
236 https://doi.org/10.18632/oncotarget.3460 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007602046
237 rdf:type schema:CreativeWork
238 https://doi.org/10.3324/haematol.2012.065151 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013692359
239 rdf:type schema:CreativeWork
240 https://doi.org/10.3324/haematol.2012.066100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032557350
241 rdf:type schema:CreativeWork
242 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
243 schema:name Gustave Roussy, Département d'hématologie et Département d'innovation Thérapeutique, F-94805, Villejuif, France.
244 Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
245 rdf:type schema:Organization
246 https://www.grid.ac/institutes/grid.240145.6 schema:alternateName The University of Texas MD Anderson Cancer Center
247 schema:name The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
248 rdf:type schema:Organization
249 https://www.grid.ac/institutes/grid.267313.2 schema:alternateName The University of Texas Southwestern Medical Center
250 schema:name UT Southwestern Medical Center, Dallas, TX, USA.
251 rdf:type schema:Organization
252 https://www.grid.ac/institutes/grid.410425.6 schema:alternateName City Of Hope National Medical Center
253 schema:name City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
254 rdf:type schema:Organization
255 https://www.grid.ac/institutes/grid.418722.a schema:alternateName Celgene (United States)
256 schema:name Celgene Corporation, Summit, NJ, USA.
257 rdf:type schema:Organization
258 https://www.grid.ac/institutes/grid.427815.d schema:alternateName Agios Pharmaceuticals (United States)
259 schema:name Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
260 rdf:type schema:Organization
261 https://www.grid.ac/institutes/grid.430503.1 schema:alternateName University of Colorado Anschutz Medical Campus
262 schema:name Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA. daniel.pollyea@ucdenver.edu.
263 rdf:type schema:Organization
264 https://www.grid.ac/institutes/grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center
265 schema:name Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
266 rdf:type schema:Organization
267 https://www.grid.ac/institutes/grid.5386.8 schema:alternateName Cornell University
268 schema:name Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
269 Weill Cornell Medical College, New York, NY, USA.
270 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...